Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Free Report) EVP Neena M. Patil sold 5,000 shares of the firm’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $109.65, for a total value of $548,250.00. Following the sale, the executive vice president now owns 36,629 shares in the company, valued at approximately $4,016,369.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Jazz Pharmaceuticals Trading Up 1.2 %
NASDAQ:JAZZ opened at $111.21 on Wednesday. The business’s 50-day moving average is $115.56 and its two-hundred day moving average is $120.62. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.27 and a quick ratio of 1.90. Jazz Pharmaceuticals plc has a 12 month low of $103.01 and a 12 month high of $146.70. The firm has a market capitalization of $7.01 billion, a PE ratio of 22.93, a price-to-earnings-growth ratio of 1.53 and a beta of 0.63.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last released its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing the consensus estimate of $4.44 by ($0.04). Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $1.01 billion. Research analysts predict that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
Several research firms have recently issued reports on JAZZ. HC Wainwright restated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Friday, May 3rd. Truist Financial restated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, March 20th. Cantor Fitzgerald restated an “overweight” rating and set a $180.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, April 10th. UBS Group cut their target price on Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating on the stock in a research report on Friday, March 1st. Finally, Barclays cut their target price on Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Friday, May 3rd. Two research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $192.75.
Get Our Latest Stock Analysis on Jazz Pharmaceuticals
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
Further Reading
- Five stocks we like better than Jazz Pharmaceuticals
- Stock Splits, Do They Really Impact Investors?
- Garmin Navigates to New Highs Driven By Wearables Trend
- What is a Death Cross in Stocks?
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- Investing in large cap stocks: Diving into big caps
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.